May 4, 2020 / 12:11 PM / 22 days ago

BRIEF-Cytodyn Says 49 COVID-19 Patients Have Enrolled For Treatment With Leronlimab Through eIND

May 4 (Reuters) - Cytodyn Inc:

* FDA APPROVES 54 EMERGENCY INDS FOR LERONLIMAB TREATMENT OF CORONAVIRUS – CYTODYN REQUESTS COMPASSIONATE USE FROM FDA FOR COVID-19 PATIENTS NOT ELIGIBLE FOR PARTICIPATION IN TWO ONGOING CLINICAL TRIALS IN U.S. – CYTODYN TARGETS ENROLLMENT COMPLETION FOR IT

* CYTODYN INC - 49 COVID-19 PATIENTS HAVE ENROLLED FOR TREATMENT WITH LERONLIMAB THROUGH EIND

* CYTODYN INC - 4 OUT OF 11 CRITICALLY ILL PATIENTS WITH PRE-EXISTING CONDITIONS SURVIVED AFTER TREATMENT WITH LERONLIMAB

* CYTODYN INC - OF NEXT 38 PATIENTS TREATED WITH LERONLIMAB, MANY WERE EXTUBATED, IMPROVED, OR WERE DISCHARGED Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below